Recent Updates
Recently added Catalysts

SSRI/Venlafaxine

Phase 3

Major Depressive Disorder | Small molecule | Psychiatry |AstraZeneca PLC|Last Updated: May 23, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment688
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00789854Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD PatientsPHASE3 COMPLETED 688Nov 1, 2008Aug 1, 2009May 23, 2012106 Australia, Austria +11
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)
6 weeks treatment

Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.

Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)
6 weeks of treatment

Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.

Secondary Endpoints
Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients
6 weeks of treatment
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure
6 weeks of treatment
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure
6 weeks of treatment
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Add-on Quetiapine XR+SSRI/VenlafaxineACTIVE_COMPARATORSelective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od). From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline.
Add-on Lithium+SSRI/VenlafaxineACTIVE_COMPARATORSelective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od). From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline.
Monotherapy Quetiapine XRACTIVE_COMPARATORSwitch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
Interventions
NameTypeDescription
Quetiapine XRDRUG300 mg once daily (od)
Lithium carbonateDRUG900 mg once daily (od)
SSRI/VenlafaxineDRUGSSRI - doses within label, Venlafaxine dose up to 225 mg/day
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites106

Inclusion Criteria: * Documented clinical diagnosis as confirmed by the M.I.N.I. meeting criteria from the Diagnostic and Statistical Manual of Mental disorders, 4th Edition (DSM-IV) for any of the following:296.2x MDD, Single Episode296.3x MDD, Recurrent Episode * Current episode of depression pre...

Countries:AustraliaAustriaBelgiumBulgariaDenmarkGermanyHungaryItalyPortugalRomaniaSlovakiaSpainUnited Kingdom
Unlock Eligibility Criteria